A drug class that redirects the immune system's own T cells has cleared a hurdle it had never cleared before. On September 8, AstraZeneca and Amgen announced that the Phase III DeLLphi-305 trial met its primary endpoint, with the combination of Imfinzi and Imdelltra producing a statistically significant and, in the companies' words, highly clinically meaningful improvement in overall survival for first-line maintenance treatment of extensive-stage small cell lung cancer.
The result is a landmark for bispecific T-cell engagers, or BiTEs, which bind a tumor marker on one side and a T cell on the other, physically pulling the immune cell onto the cancer. It is the first Phase III trial to show a survival benefit for a BiTE in the first-line setting for this disease. It is also a careful announcement: no numbers, no curves, no magnitude. The companies said detailed results will be presented at an upcoming medical meeting and shared with regulators.
What the trial tested
DeLLphi-305 enrolled 563 patients with extensive-stage small cell lung cancer whose disease had not progressed after standard induction treatment with Imfinzi plus platinum-based chemotherapy. Patients were randomized to continue with Imfinzi alone, the current standard maintenance approach, or to add Imdelltra, and treated until progression or unacceptable toxicity. The trial was sponsored by Amgen, with AstraZeneca contributing Imfinzi and partial funding.
The combination cleared the primary endpoint of overall survival at a planned interim analysis, and also showed statistically significant improvements in progression-free survival and objective response rate, the key secondary measures. The safety profile was consistent with the known profiles of each medicine, with no new or unexpected safety signals identified.
The mechanism matters to the result's meaning. Imfinzi is a PD-L1 inhibitor that lifts one brake on the immune system. Imdelltra is a first-in-class BiTE that targets DLL3, a protein expressed on roughly 85 to 96 percent of small cell lung cancers but minimally on healthy cells. The two drugs attack the disease from different angles, and DeLLphi-305 appears to show the angles add up.
The context that makes the win significant
Small cell lung cancer accounts for about 13 to 15 percent of the roughly 2.6 million lung cancer cases diagnosed worldwide each year, and about two thirds of patients are diagnosed after the disease has spread beyond the lung, the extensive-stage form. Median survival from the start of first-line maintenance is approximately one year, and only about 40 percent of patients ever reach a second line of therapy. Progress has been slow and incremental, which is why any overall survival win in this setting changes practice.
Imfinzi is already the standard of care in extensive-stage disease on the strength of the CASPIAN trial and in limited-stage disease on the strength of ADRIATIC. Imdelltra is currently approved only for previously treated small cell lung cancer. A positive DeLLphi-305 could move Imdelltra into the first-line maintenance setting, expanding its reach from the roughly 40 percent of patients who reach later lines to a much larger population at diagnosis.
The careful framing deserves equal weight. The companies have disclosed that the benefit exists and that it cleared the pre-specified bar. They have not disclosed its size, and in a disease where median survival sits near a year, the difference between a meaningful improvement and a transformative one lives entirely in numbers that are not yet public. For patients and clinicians, the appropriate reading is hopeful and incomplete: the direction is good, the magnitude is unknown, and the full data will arrive at a medical meeting still to be named.
What changes now
For regulators, the result adds to an already rich discussion about moving BiTEs earlier in treatment. For clinicians, it introduces a decision point that will not be resolvable until the detailed data appears. For Amgen and AstraZeneca, it validates a bet on DLL3 that spans multiple trials and multiple lines of therapy.
For the field, the result is a proof of concept that the BiTE mechanism can deliver survival gains where the disease's options have been thin. The class has produced impressive response rates in later lines for years; what it lacked was evidence that the responses translated into longer life in the setting where most patients live. DeLLphi-305 is the first evidence of that kind, and the standard of care in extensive-stage small cell lung cancer now has a real contender waiting in the wings.
Primary sources
- AstraZeneca press release on the DeLLphi-305 interim analysis.
- BioPharm International for the trial design and the BiTE landmark context.
- Fierce Pharma for Amgen's perspective and the regulatory implications.